Table 2. Summarized results of meta-analysis.

Outcomes of interest	Studies number	Patients number		RR(95%CI)	P-value	Heterogeneity
		Exp *	Ctrl #			Chi2	df	P-value	I 2,%
Any stroke	14	48444	48397	0.79 (0.73–0.85)	<0.00001	15.57	13	0.27	17
Short-term	6	27443	27374	0.76 (0.67–0.85)	<0.00001	7.18	5	0.21	30
Long-term	8	21001	21023	0.81(0.73–0.89)	<0.00001	7.82	7	0.35	10
Ischemic stroke ‡	10	45246	45225	0.76(0.70–0.82)	<0.00001	9.16	9	0.42	2
Short-term	4	25642	25585	0.74(0.65–0.85)	<0.00001	4.19	3	0.24	28
Long-term	6	19604	19640	0.77(0.69–0.85)	<0.00001	4.85	5	0.43	0
Hemorrhagic stroke	10	45246	45225	1.12(0.87–1.44)	0.38	4.61	6	0.59	0
Short-term	4	25642	25585	0.98(0.69–1.39)	0.92	0.00	1	0.97	0
Long-term	6	19604	19640	1.30(0.90–1.87)	0.16	3.54	4	0.47	0
Major bleeding	14	47493	47459	1.42(1.25–1.62)	<0.00001	15.57	11	0.16	29
Short-term	6	27424	27354	1.11(0.91–1.36)	0.30	0.81	3	0.85	0
Long-term	8	20069	20105	1.52(1.36–1.69)	<0.00001	7.50	7	0.38	7
Intracranial bleeding	7	30278	30197	1.25(0.98–1.61)	0.07	7.67	4	0.10	48
Short-term	4	24791	24718	0.92(0.66–1.30)	0.65	0.63	1	0.43	0
Long-term	3	5487	5479	1.76(1.22–2.54)	0.002	0.84	2	0.66	0

RR: relative risk; CI: confidence interval.

* Indicating clopidogrel plus aspirin group.

^#Indicating aspirin plus placebo group.

^¶Degree of freedom.

^‡Ischemic stroke including stroke with uncertain causes.